← Back to feed Capvaxive cleared for pediatric pneumococcal disease
Drug Capvaxive · pneumococcal 21-valent conjugate vaccine
Indication Prevention of pneumococcal disease in patients aged 2-17 at increased risk More on Merck ↗ Google News FDA approved Merck's Capvaxive (21-valent pneumococcal conjugate vaccine) for children and adolescents aged 2-17 at increased risk for pneumococcal disease. The approval expands Capvaxive from its original adult indication into the pediatric high-risk population.
Read original at drugs.com ↗ Background Drug-class context · Wikipedia Streptococcus pneumoniae is a bacterial pathogen responsible for otitis media, pneumonia, bacteraemia, and meningitis. Pneumococcal conjugate vaccines protect against invasive pneumococcal disease by conjugating capsular polysaccharides from clinically-important serotypes to a carrier protein (typically CRM197), producing a T-cell-dependent immune response that pediatric conjugate vaccines require. Capvaxive is a 21-valent formulation initially approved June 2024 for adults; the June 18, 2026 approval extends the indication to patients aged 2-17 at increased risk (those with anatomic or functional asplenia, HIV infection, chronic disease, cochlear implants, or CSF leaks). Capvaxive's 21-valent design covers the serotypes most commonly implicated in adult invasive pneumococcal disease and complements Prevnar 20 (Pfizer, 20 serotypes) and Vaxneuvance (Merck, 15 serotypes) in the current U.S. pneumococcal-vaccine landscape.
Source: Wikipedia · CC BY-SA
Topic vaccine
